Vir Biotechnology, Inc(NASDAQ:VIR) 
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of hum...
Website: http://www.vir.bio
Founded: 2016
IPO Price: $20 (Oct 11, 2019)
Full Time Employees: 297
CEO: George A. Scangos
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 5.72
H 5.84
L 5.49
C 5.58
V 1,901,512
10EMA 5.58
20EMA 5.58
60EMA 5.58
120EMA 5.58
250EMA 5.58